Information Provided By:
Fly News Breaks for June 17, 2015
ZFGN, WRLD, WWE, MRWSY, TSCDY, SFM, CRM, RSTI, RM, QRHC, PFE, PDVW, MOH, MRK, MDR, JSAIY, IIVI, HDP, FIT, LLY, CHCT, ASTE, BMY, ANET, ABBV
Jun 17, 2015 | 10:00 EDT
Today's noteworthy initiations include: AbbVie (ABBV) initiated with an Overweight at Piper Jaffray... Arista Networks (ANET) initiated with a Buy at Sterne Agee CRT... Astec (ASTE) initiated with a Buy at Maxim... Bristol-Myers (BMY) initiated with an Underweight at Piper Jaffray... Community Healthcare (CHCT) initiated with an Outperform at Oppenheimer... Eli Lilly (LLY) initiated with an Overweight at Piper Jaffray... Fitbit (FIT) initiated with a Buy ahead of IPO at Dougherty... Hortonworks (HDP) initiated with a Buy at Mizuho... II-VI (IIVI) initiated with a Buy at Benchmark Co.... J Sainsbury (JSAIY) initiated with an Underperform at Credit Suisse... McDermott (MDR) initiated with an Outperform at Cowen... Merck (MRK) initiated with a Neutral at Piper Jaffray... Molina Healthcare (MOH) initiated with a Buy at UBS... Pacific DataVision (PDVW) initiated with a Buy at Canaccord... Pfizer (PFE) initiated with an Overweight at Piper Jaffray... Quest Resource (QRHC) initiated with a Buy at Roth Capital... Regional Management (RM) initiated with a Buy at Janney Capital... Rofin-Sinar (RSTI) initiated with a Buy at Benchmark Co.... Salesforce (CRM) initiated with a Neutral at Exane BNP Paribas... Sprouts Farmers Markets (SFM) initiated with a Neutral at Cleveland Research... Tesco (TSCDY) initiated with an Underperform at Credit Suisse... WM Morrison (MRWSY) initiated with a Neutral at Credit Suisse... WWE (WWE) initiated with a Buy at BTIG... World Acceptance (WRLD) initiated with a Buy at Janney Capital... Zafgen (ZFGN) initiated with a Buy at SunTrust.
News For ABBV;ANET;BMY;ASTE;CHCT;LLY;FIT;HDP;IIVI;JSAIY;MDR;MRK;MOH;PDVW;PFE;QRHC;RM;RSTI;CRM;SFM;TSCDY;MRWSY;WWE;WRLD;ZFGN From the Last 2 Days
MOH
Mar 28, 2024 | 15:22 EDT
What has Wall Street been buzzing about this week? Here are the top 5 Bu-y calls and the top 5 Sell calls made by Wall Street’s best analysts during the week of March 25-28. Find all top-rated... To see the rest of the story go to thefly.com. See Story Here
MOH
Mar 28, 2024 | 12:00 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
MOH
Mar 28, 2024 | 06:51 EDT
BofA downgraded Molina Healthcare (MOH) to Underperform from Neutral with a $439 price target. The firm, which is concerned that Molina and the Medicaid industry more broadly are likely to face rate pressure after a period of elevated margins, sees a less attractive risk/reward for Molina compared to other insurers the firm covers, the analyst tells investors. Molina is now trading roughly at parity with the firm's top pick in the space, UnitedHealth (UNH), compared to a 22% discount that had been seen over the last five years, helping to underscore the firm's view that "sentiment for Medicaid is nearing a top just at a time when Medicare is reaching a bottom," the analyst added.
MRK
Mar 28, 2024 | 06:48 EDT
Merck announced that the European Commission has approved Keytruda, Merck's anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer at high risk of recurrence in adults.
MRK
Mar 27, 2024 | 16:24 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
MRK
Mar 27, 2024 | 12:00 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here
MRK
Mar 27, 2024 | 08:55 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly.  HIGHER - Robinhood (HOOD)... To see the rest of the story go to thefly.com. See Story Here
PFE
Mar 27, 2024 | 08:27 EDT
Pieris Pharmaceuticals (PIRS) provided a corporate update announcing a strategy to maximize its ability to capture the potential milestones from its 4-1BB bispecific Mabcalin protein immuno-oncology assets partnered with Pfizer (PFE), Boston Pharmaceuticals, and Servier. After considering an extensive range of options, the Company's Board of Directors decided to implement this new strategy along with relevant cost-saving measures that are expected to extend the Company's cash runway into 2027. The Company's strategic review process has focused on maximizing stockholder value, which includes the preservation of potential milestone and royalty payments the Company is eligible to receive. Management and the Board of Directors evaluated a broad spectrum of potential options, including asset in-licensing, out-licensing, royalty monetization, strategic transactions, and liquidation. With the assistance of the Company's retained strategic advisor, Stifel, Nicolaus & Company, more than 500 companies were contacted regarding a strategic transaction, and the Company underwent a robust process to identify and negotiate with a select number of final candidates. The Company entered into extended exclusivity with one party contemplating a strategic merger, which centered on that party's interest in developing the Company's clinical-stage asset cinrebafusp alfa, but after extensive diligence and negotiations, that counterparty was unable to secure adequate capitalization and offer acceptable terms. The Company ultimately determined that the Company's planned repositioning offers the best opportunity to maximize stockholder value. In support of optimizing potential milestones and royalties, the Company's strategic repositioning includes: A plan to maintain strategic capability by maintaining a lean and experienced Board and management profile to actively pursue the Company's strategy and consider strategic options; The discontinuation of all the Company's research and development efforts, which is expected to be completed by the middle of 2024; A workforce reduction that affects additional employees and the executive leadership team, expected to be implemented in the second quarter; A plan to reduce the size of the Company's Board of Directors, to be better aligned with the nature of the Company's continuing operations, also expected to be implemented in the second quarter. Since initiating the strategic review in July 2023, the Company implemented several steps, including scaling back operational costs, inclusive of associated headcount reductions, ceasing development of PRS-220 and PRS-400 within its respiratory franchise, and suspending investments associated with co-development of partnered assets. The Company has also eliminated its material long-term obligations through the previously disclosed termination of its lease obligation in Germany, while simultaneously continuing to improve its cash position through the sale of its laboratory and office equipment.
MRK
Mar 27, 2024 | 07:19 EDT
BofA notes that Merck shares have been volatile as investors have contemplated various scenarios regarding the approval of sotatercept and its language, including "a lot of investor angst" given the risk for the FDA to issue either black box warnings, REMS, and/or monitoring requirement. However, sotatercept's approval in PAH with the brand name Winrevair "comes with a squeaky-clean label," without WHO functional class restriction or a need to be on background therapy, no black box and no REMS, which represents "the most bullish scenario," the analyst tells investors. The firm, which anticipates Merck shares to react favorably, maintains a Buy rating and $135 price target and sees upside to sotatercept's commercial outlook.
MRK
Mar 27, 2024 | 06:12 EDT
Wells Fargo raised the firm's price target on Merck to $135 from $130 and keeps an Equal Weight rating on the shares. The firm notes WINREVAIR, or sotatercept, was approved with simple monitoring on the label, removing an overhang on the stock. $242k annual pricing is competitive and could enable the drug to move into earlier lines, and Wells now models $7B peak sales opportunity.
JSAIY
Mar 27, 2024 | 05:07 EDT
UBS analyst Sreedhar Mahamkali upgraded J Sainsbury to Buy from Neutral with a price target of 295 GBp, up from 275 GBp. The analyst believes the market is not fully reflecting the company's mid-term margin and cash return potential while the stock pullback offers a good entry point.